曲妥珠单抗德曲妥珠单抗用于HER2过表达的非小细胞肺癌（NSCLC）。 - Suppr

Suppr

超能文献

Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC).

作者信息

Pitiyarachchi Omali, Tan Aaron C

机构信息

School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

出版信息

Transl Lung Cancer Res. 2025 Feb 28;14(2):314-322. doi: 10.21037/tlcr-24-968. Epub 2025 Feb 24.

DOI:10.21037/tlcr-24-968

PMID:40114960

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11921179/

Abstract

摘要

相似文献

Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC).曲妥珠单抗德曲妥珠单抗用于HER2过表达的非小细胞肺癌（NSCLC）。

Transl Lung Cancer Res. 2025 Feb 28;14(2):314-322. doi: 10.21037/tlcr-24-968. Epub 2025 Feb 24.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.曲妥珠单抗-德鲁替康用于转移性非小细胞肺癌患者（DESTINY-Lung01）：一项单臂、2 期临床试验中 HER2 过表达队列的主要结果。

Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.

Evolving Treatment Landscape of -mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond.-突变型非小细胞肺癌不断演变的治疗格局：曲妥珠单抗德鲁替康及其他。

Cancers (Basel). 2023 Feb 17;15(4):1286. doi: 10.3390/cancers15041286.

Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.非小细胞肺癌中高水平 ERBB2 扩增的流行率和治疗靶点。

J Thorac Oncol. 2024 May;19(5):732-748. doi: 10.1016/j.jtho.2023.12.019. Epub 2023 Dec 26.

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.曲妥珠单抗-德鲁替康（DS-8201a），一种 HER2 靶向抗体药物偶联物，在体外和体内对过表达 HER2 的原发性和转移性卵巢肿瘤均显示出抗肿瘤活性。

Clin Exp Metastasis. 2024 Oct;41(5):765-775. doi: 10.1007/s10585-024-10297-z. Epub 2024 Jun 22.

Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。

N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.

Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic -positive NSCLC: a case report and literature review.曲妥珠单抗德鲁替康治疗转移性HER2阳性非小细胞肺癌患者的疗效及迟发性免疫相关事件：1例病例报告及文献综述

Front Oncol. 2025 Jan 17;14:1469438. doi: 10.3389/fonc.2024.1469438. eCollection 2024.

Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.曲妥珠单抗 deruxtecan（DS8201）治疗 HER2 外显子 20 插入突变的晚期非小细胞肺癌：一例报告。

Anticancer Drugs. 2024 Jan 1;35(1):101-108. doi: 10.1097/CAD.0000000000001535. Epub 2023 Aug 25.

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.将 DNA 修复途径作为治疗靶点，与曲妥珠单抗-德鲁替康联合应用于 HER2 靶向抗体偶联药物耐药的 HER2 过表达乳腺癌。

J Exp Clin Cancer Res. 2024 Aug 21;43(1):236. doi: 10.1186/s13046-024-03143-3.

Metastatic -amplified non-small-cell lung cancer treated with trastuzumab deruxtecan.接受曲妥珠单抗德鲁昔单抗治疗的转移性扩增非小细胞肺癌。

BMJ Case Rep. 2023 May 8;16(5):e253260. doi: 10.1136/bcr-2022-253260.

本文引用的文献

Dermatofibrosarcoma Protuberans, Version 1.2025, NCCN Clinical Practice Guidelines In Oncology.隆突性皮肤纤维肉瘤，第1.2025版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南

J Natl Compr Canc Netw. 2025 Jan;23(1). doi: 10.6004/jnccn.2025.0001.

Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.出版商更正：曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验。

Nat Med. 2024 Dec;30(12):3780. doi: 10.1038/s41591-024-03349-0.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.达泊托单抗德卢替康与多西他赛用于既往治疗过的晚期或转移性非小细胞肺癌：随机、开放标签的III期TROPION-Lung01研究

J Clin Oncol. 2025 Jan 20;43(3):260-272. doi: 10.1200/JCO-24-01544. Epub 2024 Sep 9.

Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.曲妥珠单抗 deruxtecan 治疗人表皮生长因子受体 2（HER2）阳性的晚期结直肠癌（DESTINY-CRC02）：一项多中心、随机、2 期临床试验的主要结果。

Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5.

Human Epidermal Growth Factor Receptor 2 Pan Tumor Indication for Trastuzumab Deruxtecan.曲妥珠单抗德鲁昔单抗的人表皮生长因子受体2全肿瘤适应症

J Clin Oncol. 2024 Dec 10;42(35):4130-4133. doi: 10.1200/JCO.24.00884. Epub 2024 Aug 5.

Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer.曲妥珠单抗 deruxtecan 对比曲妥珠单抗 emtansine 用于亚洲人 HER2 阳性转移性乳腺癌患者。

Cancer Sci. 2024 Sep;115(9):3079-3088. doi: 10.1111/cas.16234. Epub 2024 Jul 9.

Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.采用高灵敏度检测方法定量测量非小细胞肺癌中的 HER2 表达。

Mod Pathol. 2024 Sep;37(9):100556. doi: 10.1016/j.modpat.2024.100556. Epub 2024 Jul 2.

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study.曲妥珠单抗 deruxtecan 治疗携特定激活 HER2 突变的实体瘤患者（DESTINY-PanTumor01）：一项国际、2 期研究。

Lancet Oncol. 2024 Jun;25(6):707-719. doi: 10.1016/S1470-2045(24)00140-2. Epub 2024 May 3.

Lancet Oncol. 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0.

Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.乳腺癌新辅助治疗前后预处理活检和残留疾病中 HER2 表达的演变。

Eur J Cancer. 2024 Apr;201:113920. doi: 10.1016/j.ejca.2024.113920. Epub 2024 Feb 10.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验